+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Facial Injectables Market by Type (Anti-aging Injections, Dermal Fillers), End User (Beauty Clinics, Dermatology Clinics, Dermatology Research Institutes) - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 4995152
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Facial Injectables Market size was estimated at USD 17.30 billion in 2023, USD 19.30 billion in 2024, and is expected to grow at a CAGR of 11.77% to reach USD 37.72 billion by 2030 .

Facial injectables are medical treatments administered through injections to enhance facial aesthetics, rejuvenate skin, and treat various signs of aging. They are minimally invasive procedures that can temporarily improve skin tone, texture, and structure. The rising demand for minimally invasive aesthetic treatments, technological advancements in product development, and increased disposable income enable more individuals to afford such procedures. However, the high cost of procedures and the risk of complications and adverse effects post-injection is a significant concerns that can deter potential clients. Nevertheless, advancements in personalized medicine, such as customized injectables tailored to individual facial anatomy and desired outcomes, offer untapped potential coupled with ongoing research into the safety and efficacy of these treatments, which is expected to create lucrative opportunities for the facial injectables market.

Regional Insights

The facial injectables market is evolving in the Americas, driven by heightened consumer awareness, a growing aging population, and a strong culture of cosmetic enhancement. There is a significant investment in R&D, with companies constantly innovating to gain a competitive edge, as seen in the latest patents for longer-lasting and safer fillers. Providers are also increasingly tailoring their products and services to cater to diverse ethnic groups and individual preferences. Furthermore, consumers value natural-looking results, prompting providers to adopt techniques and products that deliver subtlety and precision. The facial injectables market across EU countries varies widely due to differing regulatory restrictions, cultural perceptions, and economic status. A preference for natural appearance and conservative approaches to cosmetic procedures generally distinguishes the EU market. Regulatory innovations such as the EU's Medical Device Regulation (MDR) are reshaping standards and practices within the industry. The MEA region presents a diverse landscape, with the Middle East accounting for a substantial share of demand due to the high per capita expenditure on cosmetic procedures in many countries. The African market shows potential with rising urbanization and economic development in certain countries. Both regions exhibit an increased awareness of anti-aging treatments, driving the market for facial injectables. The Asia-Pacific facial injectables market is burgeoning, with a sharp growth in the acceptance of aesthetic procedures among middle-aged and younger cohorts looking to enhance their appearances. The market is also witnessing local investments and the emergence of domestic players challenging international brands, capitalizing on the growing middle class's purchasing power. Furthermore, consumers prefer high-quality and technologically advanced products, demonstrated by their quick adoption of novel injectables. The country's regulatory emphasis also informs the market on safety and precision in aesthetic medicine.

Type: Burgeoning preference for anti-aging injections due to its ability to restore facial volumes

Anti-aging injections encompass a range of products designed to decrease the signs of aging by smoothing wrinkles and restoring facial volume. They work by relaxing the facial muscles or filling in wrinkles and are administered by healthcare professionals. Botulinum Toxin A is a neuromodulator used to relax facial muscles temporarily. It is one of the most popular anti-aging treatments for lowering the appearance of dynamic wrinkles, particularly in the upper face, such as forehead lines, crow's feet, and frown lines. Poly-L-Lactic Acid (PLLA) is a biodegradable synthetic substance used as microparticles. As a stimulatory filler, PLLA is administered to the deeper layers of the skin to help stimulate the skin's production of collagen over time, gradually increasing skin thickness and smoothing wrinkles. Dermal fillers are injectable products utilized to add volume, change the contours of the face, and fill in wrinkles. Common areas for treatment comprise the lips, cheeks, nasolabial folds, and marionette lines. Fillers are composed of various substances, some naturally occurring and some synthetic. Collagen fillers are derived from either human or animal collagen and are used to supplement the body's natural collagen, which depletes with age. These fillers can improve the appearance of fine lines and wrinkles and provide a moderate lifting effect, but they tend to break down faster than other filler types. Hyaluronic acid is a naturally arising substance in the skin that retains moisture and creates a plump and hydrated look. Hyaluronic acid fillers are used for facial injections because of their compatibility with the body and can dissolve naturally over time. They are commonly used for lip augmentation, contouring, and treating medium to severe facial folds and wrinkles. Synthetic fillers comprise lab-made substances that do not naturally occur in the skin. These fillers, such as calcium hydroxylapatite, polylactic acid, and polymethylmethacrylate beads, provide longer-lasting results than those with substances that are absorbed by the body and are used for deep wrinkles, volume loss, and facial contouring.

End User: Evolving adoption of facial injectables by dermatology clinics

Beauty clinics represent a significant segment of facial injectables, given their specialization in cosmetic procedures. These establishments commonly provide a variety of non-surgical aesthetic treatments, including Botox, dermal fillers, and other injectables aimed at enhancing facial features and reducing signs of aging. Dermatology clinics are a critical end-user of facial injectables. These medical facilities are operated by board-certified dermatologists who administer injectables as part of a broader range of skin health services. Facial injectables in these settings are used for aesthetic enhancement and therapeutic purposes, such as treating medical conditions, including hyperhidrosis or certain types of migraines. Dermatology Research Institutes are pivotal in advancing facial injectable products and techniques. These institutions prioritize facial injectables that have the potential for innovation and breakthroughs in dermatological science. They may work directly with manufacturers in clinical trials or studies to evaluate long-term efficacy and safety. Preference is given to products that allow researchers to explore new populations, indications, or delivery methods. Hospitals' use of facial injectables revolves around reconstructive or therapeutic treatments rather than cosmetic enhancements. Patients may receive facial injectables for rehabilitation after traumatic injuries or surgeries or for the treatment of medical conditions such as migraines or excessive sweating. Hospitals prefer versatile products, have a strong safety record, and are cost-effective, especially when dealing with medical insurance and budget constraints.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Facial Injectables Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Facial Injectables Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Facial Injectables Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Facial Injectables Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Facial Injectables Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Facial Injectables Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Facial Injectables Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Facial Injectables Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Facial Injectables Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Facial Injectables Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Facial Injectables Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Facial Injectables Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Facial Injectables Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

DAXXIFY Becomes First Facial Injectable to be Named to TIME’s Best Inventions

Revance Therapeutics announced that its pioneering neuromodulator, DAXXIFY (daxibotulinumtoxinA-lanm) for Injection, has been heralded as one of TIME’s Best Inventions of 2023, which is an impressive achievement highlighting the substance's groundbreaking impact on the aesthetic industry. Poised as a major disruptor in the USD 2.5 billion U.S. neuromodulator market, DAXXIFY stands out as the first U.S. manufactured, peptide-formulated neuromodulator to offer a much-desired longer lasting effect, meeting the demands of 90% of patients and practitioners.

SKINVIVE by JUVÉDERM Receives U.S. FDA Approval

Allergan Aesthetics, a subsidiary of AbbVie, announced the FDA's approval of their advance SKINVIVE by JUVÉDERM. Amidst the surge in the facial injectables sector, SKINVIVE by JUVÉDERM heralds a paradigm shift, targeting skin smoothness and hydration rather than volume enhancement. It uniquely caters to all Fitzpatrick Skin Types I-VI and is commended by industry professionals for increasing skin hydration without frequent treatment sessions.

Symatese Announces Its Partnership With Evolus In The USA Regarding Its New Range Of HA Dermal Fillers

Symatese, an entity in the aesthetic medicine sector, reached a milestone by finalizing a strategic partnership with Evolus, a key industry player in the U.S. market. This collaboration centers on the global commercialization of Symatese's innovative dermal fillers, underpinned by its pioneering First-Generation Cold Technology HA, a testament to the company's commitment to leading-edge product development.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Facial Injectables Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Facial Injectables Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanced Dermatology and Cosmetic Surgery, ALPHAEON Corporation, Anika Therapeutics, Inc, Antares Pharma, Inc. by Halozyme Therapeutics, Inc., Bausch Health Companies Inc., Becton, Dickinson and Company, Bloomage BioTechnology Corporation Limited, Eisai Co., Ltd., Fidia Farmaceutici S.p.A., Galderma Laboratories, L.P., Galderma S.A., Inovio Pharmaceuticals Inc., Ipsen Pharma, Johnson & Johnson Services, Inc., Mastelli Srl, Medytox Inc., Merz Pharma GmbH & Co KGaA, Novartis AG, Pfizer Inc., Prollenium Medical Technologies Inc., Remedium Korea, Sanofi S.A., Sinclair Pharma Group, Suneva Medical, Inc., and Zimmer Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Facial Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Anti-aging Injections
      • Botulinum Toxin A
      • Poly-L-Lactic Acid (PLLA) Micro Particles
    • Dermal Fillers
      • Collagen Fillers
      • Hyaluronic Acid
      • Synthetic Fillers
  • End User
    • Beauty Clinics
    • Dermatology Clinics
    • Dermatology Research Institutes
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Facial Injectables Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing Disposable Income Among People and Increased Demand for Cosmetic Procedures
5.1.1.2. Increasing Focus on Physical Appearance Among Consumers Globally
5.1.1.3. Rising Inclination Toward Minimally Invasive Procedures Among People
5.1.2. Restraints
5.1.2.1. Limited Reimbursement Policies Supporting Cosmetic Procedures
5.1.3. Opportunities
5.1.3.1. Introduction of New Fillers and Anti-Aging Botulinum Toxin Injection Therapies coupled with Regulatory Approvals
5.1.3.2. Rise in the Cosmetic Tourism
5.1.4. Challenges
5.1.4.1. Strict Regulatory Concerns about Facial Injectable Products and Relative Side Effects
5.2. Market Segmentation Analysis
5.2.1. Type: Burgeoning preference for anti-aging injections due to its ability to restore facial volumes
5.2.2. End User: Evolving adoption of facial injectables by dermatology clinics
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
6. Facial Injectables Market, by Type
6.1. Introduction
6.2. Anti-aging Injections
6.3. Dermal Fillers
7. Facial Injectables Market, by End User
7.1. Introduction
7.2. Beauty Clinics
7.3. Dermatology Clinics
7.4. Dermatology Research Institutes
7.5. Hospitals
8. Americas Facial Injectables Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Facial Injectables Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Facial Injectables Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. DAXXIFY Becomes First Facial Injectable to be Named to TIME’s Best Inventions
11.3.2. SKINVIVE by JUVÉDERM Receives U.S. FDA Approval
11.3.3. Symatese Announces Its Partnership With Evolus In The USA Regarding Its New Range Of HA Dermal Fillers
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. FACIAL INJECTABLES MARKET RESEARCH PROCESS
FIGURE 2. FACIAL INJECTABLES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL FACIAL INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. FACIAL INJECTABLES MARKET DYNAMICS
FIGURE 7. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. FACIAL INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. FACIAL INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. FACIAL INJECTABLES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL FACIAL INJECTABLES MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL FACIAL INJECTABLES MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN A, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN A, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY POLY-L-LACTIC ACID (PLLA) MICRO PARTICLES, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY POLY-L-LACTIC ACID (PLLA) MICRO PARTICLES, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY COLLAGEN FILLERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY COLLAGEN FILLERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY SYNTHETIC FILLERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY SYNTHETIC FILLERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY BEAUTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY BEAUTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMATOLOGY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DERMATOLOGY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 49. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 50. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 51. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 52. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 55. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 56. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 57. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 58. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 59. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 60. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 61. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 62. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 63. CANADA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 64. CANADA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 65. CANADA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 66. CANADA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 67. CANADA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 68. CANADA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 69. CANADA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 70. CANADA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 71. MEXICO FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 72. MEXICO FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 73. MEXICO FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 74. MEXICO FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 75. MEXICO FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 76. MEXICO FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 77. MEXICO FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 78. MEXICO FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 79. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 80. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 81. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 82. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 87. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 88. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 90. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 92. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 98. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 99. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 100. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 101. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 102. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 103. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 104. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 105. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 106. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 107. CHINA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 108. CHINA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 109. CHINA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 110. CHINA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 111. CHINA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 112. CHINA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 113. CHINA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 114. CHINA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 115. INDIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 116. INDIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 117. INDIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 118. INDIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 119. INDIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 120. INDIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 121. INDIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 122. INDIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 123. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 124. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 125. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 126. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 127. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 128. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 129. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 130. INDONESIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 131. JAPAN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 132. JAPAN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 133. JAPAN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 134. JAPAN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 135. JAPAN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 136. JAPAN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 137. JAPAN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 138. JAPAN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 139. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 140. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 141. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 142. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 143. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 144. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 145. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 146. MALAYSIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 147. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 148. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 149. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 150. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 151. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 152. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 153. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 154. PHILIPPINES FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 155. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 156. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 157. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 158. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 159. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 160. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 161. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 162. SINGAPORE FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 163. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 164. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 165. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 166. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 167. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 168. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 169. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 170. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 171. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 172. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 173. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 174. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 175. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 176. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 177. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 178. TAIWAN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 179. THAILAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 180. THAILAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 181. THAILAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 182. THAILAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 183. THAILAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 184. THAILAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 185. THAILAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 186. THAILAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 187. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 188. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 189. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 190. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 191. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 192. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 193. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 194. VIETNAM FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 205. DENMARK FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 206. DENMARK FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 207. DENMARK FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 208. DENMARK FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 209. DENMARK FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 210. DENMARK FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 211. DENMARK FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 212. DENMARK FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 213. EGYPT FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 214. EGYPT FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 215. EGYPT FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 216. EGYPT FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 217. EGYPT FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 218. EGYPT FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 219. EGYPT FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 220. EGYPT FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 221. FINLAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 222. FINLAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 223. FINLAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 224. FINLAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 225. FINLAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 226. FINLAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 227. FINLAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 228. FINLAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 229. FRANCE FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 230. FRANCE FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 231. FRANCE FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 232. FRANCE FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 233. FRANCE FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 234. FRANCE FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 235. FRANCE FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 236. FRANCE FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 237. GERMANY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 238. GERMANY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 239. GERMANY FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 240. GERMANY FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 241. GERMANY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 242. GERMANY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 243. GERMANY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 244. GERMANY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 245. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 246. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 247. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 248. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 249. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 250. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 251. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 252. ISRAEL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 253. ITALY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 254. ITALY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 255. ITALY FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 256. ITALY FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 257. ITALY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 258. ITALY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 259. ITALY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 260. ITALY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 261. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 262. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 263. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 264. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 265. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 266. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 267. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 268. NETHERLANDS FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 269. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 270. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 271. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 272. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 273. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 274. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 275. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 276. NIGERIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 277. NORWAY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. NORWAY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. NORWAY FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 280. NORWAY FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 281. NORWAY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 282. NORWAY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 283. NORWAY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 284. NORWAY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 285. POLAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 286. POLAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 287. POLAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 288. POLAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 289. POLAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 290. POLAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 291. POLAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 292. POLAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 293. QATAR FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 294. QATAR FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 295. QATAR FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 296. QATAR FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 297. QATAR FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 298. QATAR FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 299. QATAR FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 300. QATAR FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 301. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 302. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 303. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 304. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 305. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 306. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 307. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 308. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 310. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 312. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 314. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 316. SAUDI ARABIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 318. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 320. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 322. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 324. SOUTH AFRICA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 325. SPAIN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 326. SPAIN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 327. SPAIN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 328. SPAIN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 329. SPAIN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 330. SPAIN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 331. SPAIN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 332. SPAIN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 333. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 334. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 335. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 336. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 337. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 338. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 339. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 340. SWEDEN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 341. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 342. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 343. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 344. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2024-2030 (USD MILLION)
TABLE 345. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2023 (USD MILLION)
TABLE 346. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2024-2030 (USD MILLION)
TABLE 347. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 348. SWITZERLAND FACIAL INJECTABLES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 349. TURKEY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 350. TURKEY FACIAL INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 351. TURKEY FACIAL INJECTABLES MARKET SIZE, BY ANTI-AGING INJECTIONS, 2018-2023 (USD MILLION)
TABLE 352. TURKEY FACIAL IN

Companies Mentioned

  • AbbVie Inc.
  • Advanced Dermatology and Cosmetic Surgery
  • ALPHAEON Corporation
  • Anika Therapeutics, Inc
  • Antares Pharma, Inc. by Halozyme Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Becton, Dickinson and Company
  • Bloomage BioTechnology Corporation Limited
  • Eisai Co., Ltd.
  • Fidia Farmaceutici S.p.A.
  • Galderma Laboratories, L.P.
  • Galderma S.A.
  • Inovio Pharmaceuticals Inc.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Mastelli Srl
  • Medytox Inc.
  • Merz Pharma GmbH & Co KGaA
  • Novartis AG
  • Pfizer Inc.
  • Prollenium Medical Technologies Inc.
  • Remedium Korea
  • Sanofi S.A.
  • Sinclair Pharma Group
  • Suneva Medical, Inc.
  • Zimmer Holdings, Inc.

Methodology

Loading
LOADING...

Table Information